STOPNET

Protocol Title

A randomized study of cessation of somatostatin analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine tumours (STOPNET)

Purpose of the Study

Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not.

The aim of this randomised study is to compare the outcomes (progression free survival, cost effectiveness, and overall quality of life) of patients with well or moderately differentiated mid or hindgut neuroendocrine tumours, in whom SSA therapy is continued or ceased prior to PRRT initiation.

Contact Email

agitg@gicancer.org.au

DETAILED INFORMATION AVAILABLE

More detailed information to come.

STUDY CHAIRS

Dr Matthew Burge
A/Prof David Wyld
Dr David Pattison

Funding

Philanthropic funding
Tour De Cure grant funding